Radiopharm Theranostics Ltd (ASX: RAD) Share Price and News

Mr Hopper is founder and Executive Chairman since February 2021. He brings 20 years' experience in the management and funding of biotechnology and healthcare companies in Australia and the United States.

Mr Turner, since August 2022 he is non-executive director at AtomVie Global Radiopharma Inc, a global contract development and manufacturing organization, launched by the Centre for Probe Development and Commercialization (CPDC). He was a director of Coqui Pharmaceuticals from November 2014 to March 2019. He was Chief Executive Officer at Siemens Radiopharmaceuticals, which operated a large global PET radio-pharmacy network, from 2010 to 2012.

Mr Canevari has been our Chief Executive Officer and Managing Director since September 2021. He was previously Chief Commercial Officer of Novartis company, Advanced Accelerator Applications. Prior to that, he was Senior Vice President and Global Head of the Breast Cancer Franchise for Novartis Oncology from 2017. He has also held various management roles with Novartis Pharma and Ethicon/Johnson & Johnson.

Ms Larkin has been a Director of Radiopharm since February 2022. She is currently the Managing Director of Hester Larkin Associates Consulting. Since 2008 in this role, she has been providing consulting services to diagnostic imaging, pharmaceutical and biotech companies in projects ranging from pre-clinical, clinical, submission to the European Medicines Agency, EU medical advisory boards, EU manufacturing and commercial partnerships. She has also held several board director and trustee positions in the United Kingdom and Belgium and currently sits on the board of directors of two charities.

Mr. Donnelly is a finance and R&D executive with leadership experience in strategy, portfolio management, financial planning and analysis; project management, business partnering, valuation, decision support analysis as well as building, leading and managing functional/cross-functional teams. In addition to his role as a Director of Radiopharm, He has been the Chief Financial Officer of PEPGEN Inc.

Mr Goodwin is in the life sciences sector, bringing over four decades of experience across global healthcare and biopharmaceutical industries. He currently serves as a Non Executive Director across six organisations operating within the healthcare sector. Mr Goodwins career includes more than three decades with the Janssen Pharmaceutical Companies of Johnson & Johnson, during which he held senior leadership roles across multiple countries and regions. He has served on industry peak body boards in Australia and Japan, contributing to policy development, regulatory dialogue, and cross-sector collaboration.

-

-

-

-

-